Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 31:12:898764.
doi: 10.3389/fonc.2022.898764. eCollection 2022.

Advances in Clinical Oncology Research on 99mTc-3PRGD2 SPECT Imaging

Liming Xiao  1 , Jun Xin  1
Affiliations
Review

Advances in Clinical Oncology Research on 99mTc-3PRGD2 SPECT Imaging

Liming Xiao et al. Front Oncol. .

Abstract

The integrin alpha(α)v beta(β)3 receptor is ubiquitous in malignant tumors and has a certain level of specificity for tumors. Technetium-99m hydrazinonicotinamide-dimeric cyclic arginyl-glycyl-aspartic acid peptide with three polyethylene glycol spacers (99mTc-3PRGD2) can bind specifically to the integrin αvβ3 receptor with high selectivity and strong affinity. Thus, it can specifically mark tumors and regions with angiogenesis for tumor detection and be used in single-photon emission computed tomography (SPECT) imaging. This modality has good application value for diagnosing and treating tumor lesions, such as those in the lung, breast, esophagus, head, and neck. This review provides an overview of the current clinical research progress of 99mTc-3PRGD2 SPECT imaging for tumor lesions, including for the diagnosis and differential diagnosis of tumors in different body parts, evaluation of related metastases, and evaluation of efficacy. In addition, the future clinical application prospects and possibilities of 99mTc-3PRGD2 SPECT imaging are further discussed.

Keywords: 99mTc-3PRGD2; integrin αvβ3 receptor; molecular imaging; oncology; single-photon emission computed tomography (SPECT).

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin (2021) 71(3):209–49. doi: 10.3322/caac.21660 - DOI - PubMed
    1. Jin H, Varner J. Integrins. Roles in Cancer Development and as Treatment Targets. Br J Cancer (2004) 90(3):561–5. doi: 10.1038/sj.bjc.6601576 - DOI - PMC - PubMed
    1. Niu G, Chen X. Why Integrin as a Primary Target for Imaging and Therapy. Theranostics (2011) 1:30–47. doi: 10.7150/thno/v01p0030 - DOI - PMC - PubMed
    1. Serini G, Valdembri D, Bussolino F. Integrins and Angiogenesis: A Sticky Business. Exp Cell Res (2006) 312(5):651–8. doi: 10.1016/j.yexcr.2005.10.020 - DOI - PubMed
    1. Wolfenson H, Iskratsch T, Sheetz MP. Early Events in Cell Spreading as a Model for Quantitative Analysis of Biomechanical Events. Biophys J (2014) 107(11):2508–14. doi: 10.1016/j.bpj.2014.10.041 - DOI - PMC - PubMed

LinkOut - more resources